October 17, 2018
The U.S. Food and Drug Administration (FDA) has authorized the next-generation sequencing (NGS)–based clonoSEQ assay for the measurement of minimal residual disease (MRD) in patients with acute lymphocytic leukaemia (ALL) or multiple myeloma (MM). This is the first NGS-based test approved for this purpose. The FDA’s approval was based on results from a retrospective analysis...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand